Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

Interpretation of Research on the Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma Following Anti-BCMA Therapies Academic Background Multiple myeloma (MM) is a malignancy stemming from plasma cells within the bone marrow. Recent advancements in treatment have significantly improved overall survival rates. How...

Intrathecal Bivalent CAR T Cells Targeting EGFR and IL13Rα2 in Recurrent Glioblastoma: Phase 1 Trial Interim Results

Intrathecal Bivalent CAR T Cells Targeting EGFR and IL13Rα2 in Recurrent Glioblastoma: Phase 1 Trial Interim Results

The Effectiveness of Bivalent CAR T-Cell Therapy Targeting EGFR and IL13Rα2 in Treating Recurrent Glioblastoma In recent years, the treatment of recurrent glioblastoma (RGBM) has been continually explored and improved, yet overall survival rates remain less than one year, presenting a significant challenge. The limitations of existing treatments an...